{"id":26137,"date":"2022-07-26T13:50:42","date_gmt":"2022-07-26T12:50:42","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=26137"},"modified":"2022-07-26T13:50:46","modified_gmt":"2022-07-26T12:50:46","slug":"one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/","title":{"rendered":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022"},"content":{"rendered":"\n<p>This report describes the current climate for antimicrobial innovation. It discusses regulatory challenges and<br>opportunities for the approval of new antibiotics in three emerging markets: South Africa, Brazil, and India. <\/p>\n\n\n\n<p>The report is informed by reviews and analyses of several sources, including organizational reports, peer-reviewed<br>literature, and press releases. <\/p>\n\n\n\n<p>Semistructured interviews with experts from international organizations and the scientific and regulatory ecosystem in the three countries were conducted between November 2021 and February 2022 to obtain global and national perspectives on the regulatory landscape for antibiotics.<\/p>\n\n\n\n<p>Download report <a href=\"https:\/\/cddep.org\/wp-content\/uploads\/2022\/06\/Drug-Regulatory-Approvals-and-Opportunities-for-Antimicrobial-Innovation_July-2022.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This report describes the current climate for antimicrobial innovation. It discusses regulatory challenges andopportunities for the approval of new antibiotics in three emerging markets: South Africa, Brazil, and India. The report is informed by reviews and analyses of several sources, including organizational reports, peer-reviewedliterature, and press releases. Semistructured interviews with experts from international organizations and [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":26143,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[37],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-26T12:50:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-26T12:50:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"604\" \/>\n\t<meta property=\"og:image:height\" content=\"338\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022\",\"datePublished\":\"2022-07-26T12:50:42+00:00\",\"dateModified\":\"2022-07-26T12:50:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\"},\"wordCount\":105,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg\",\"articleSection\":[\"Bilans, rapports et recommandations\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\",\"name\":\"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg\",\"datePublished\":\"2022-07-26T12:50:42+00:00\",\"dateModified\":\"2022-07-26T12:50:46+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg\",\"width\":604,\"height\":338,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Reviews, reports and recommendations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/","og_locale":"en_GB","og_type":"article","og_title":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2022-07-26T12:50:42+00:00","article_modified_time":"2022-07-26T12:50:46+00:00","og_image":[{"width":604,"height":338,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022","datePublished":"2022-07-26T12:50:42+00:00","dateModified":"2022-07-26T12:50:46+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/"},"wordCount":105,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg","articleSection":["Bilans, rapports et recommandations"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/","name":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg","datePublished":"2022-07-26T12:50:42+00:00","dateModified":"2022-07-26T12:50:46+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg","width":604,"height":338,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"Reviews, reports and recommendations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/"},{"@type":"ListItem","position":4,"name":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-14 17:51:04","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/26137"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=26137"}],"version-history":[{"count":9,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/26137\/revisions"}],"predecessor-version":[{"id":26159,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/26137\/revisions\/26159"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/26143"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=26137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=26137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=26137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}